Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard ... the 18 patients who received the standard regimen ...

and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing ...

Tecentriq is a monoclonal antibody designed to bind with PD-L1 ... interactions with both PD-1 and B7.1 receptors. In this way, atezolizumab may enable the reactivation of T-cells, though it ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and ... free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC ...

Vilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed ... in combination with atezolizumab (Tecentriq ®) at 1200 mg ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ... to develop novel tumor-activated, antibody-based immunotherapies ...